| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC8733 | R406 Featured | R406 is a potent Syk inhibitor with IC50 of 41 nM and also potently inhibits Flt3. |
|
| DC9841 | Fostamatinib(R788) Featured | R788 (Fostamatinib), a prodrug of the active metabolite R406, is a potent Syk inhibitor with IC50 of 41 nM. |
|
| DC10995 | R916562 | R916562 (R562) is a potent, dual Axl/VEGF-R2 inhibitor with celluar IC50 of 136 nM for Axl. |
|
| DC1013 | R788 disodium (Fostamatinib) Featured | R935788 (Fostamatinib disodium, R788) is a Syk inhibitor with IC50 of 41 nM. |
|
| DC9777 | Regorafenib monohydrate（BAY 73-4506） Featured | Regorafenib (BAY 73-4506) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM, respectively. |
|
| DC1030 | Regorafenib (BAY73-4506,Fluoro-Sorafenib) Featured | Regorafenib (BAY 73-4506, Fluoro-Sorafenib) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM, respectively. |
|
| DC10463 | Repotrectinib(TPX-005) Featured | Repotrectinib(TPX-005) is a multi-target macrocycle inhibitor of anaplastic lymphoma kinase (ALK), c-ros proto-oncogene 1 receptor tyrosine kinase (ROS1), and neurotrophic tyrosine kinase receptor (TRK) |
|
| DC9857 | RG-13022 Featured | RG-13022 is an inhibitor of epidermal growth factor (EGF) receptor kinase with an IC50 value of 1 µM in HT-22 cells. |
|
| DC10367 | RG14620 Featured | RG14620 is an epidermal growth factor receptor (EGFR) inhibitor, with IC50 values of 3 μM for HER 14 colony formation and 1 pM for HER 14 DNA synthesis. |
|
| DC12372 | RK-24466 Featured | RK-24466 (KIN 001-51) is a potent and selective Lck inhibitor; inhibits Lck (64-509) and LckCD isoforms with IC50s of less than 1 and 2 nM, respectively. |
|
| DC5146 | RN486 Featured | RN-486 is a Bruton's tyrosine kinase (Btk) inhibitor. |
|
| DC9759 | RO0921 Featured | RO0921 is a novel, potent SYK inhibitor. |
|
| DC11690 | RU-302 Featured | RU-302 is a small molecule pan-TAM inhibitor that targets the TAM Ig1-Gas6 interface, blocks Gas6-dependent TAM activation. |
|
| DC10479 | RX518(CK-101:EGFR-IN-3) Featured | RX518(CK-101) is an orally available third-generation and selective inhibitor of certain epidermal growth factor receptor (EGFR) activating mutations. |
|
| DC11265 | S49076 (hydrochloride) Featured | S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab. |
|
| DC10071 | S49076 Featured | S49076 is a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3 with IC50 values below 20 nM. |
|
| DC7078 | AZD-8931(Sapitinib) Featured | Sapitinib(AZD8931) is a reversible, ATP competitive inhibitor of EGFR, ErbB2 and ErbB3 with IC50 of 4 nM, 3 nM and 4 nM respectively. |
|
| DC7672 | SAR125844 Featured | SAR125844 is inhibitor of the proto-oncogene c-Met (also known as hepatocyte growth factor receptor [HGFR]) with potential antineoplastic activity. |
|
| DC8530 | SAR131675 Featured | SAR131675 is a potent and selective VEGFR-3 inhibitor. |
|
| DC7276 | Saracatinib (AZD0530) Featured | Saracatinib (AZD0530) is a potent Src inhibitor with IC50 of 2.7 nM, and potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR (L858R and L861Q). |
|
| DC7290 | Semaxanib (SU5416) Featured | Semaxanib (SU5416) is a potent and selective VEGFR(Flk-1/KDR) inhibitor with IC50 of 1.23 μM, 20-fold more selective for VEGFR than PDGFRβ, lack of activity against EGFR, InsR and FGFR. |
|
| DC8535 | SGI-7079 Featured | SGI-7079 is a novel Axl inhibitor. |
|
| DC7294 | SGX-523 Featured | SGX-523 is a selective Met inhibitor with IC50 of 4 nM, no activity to BRAFV599E, c-Raf, Abl and p38α. |
|
| DC10632 | Sitravatinib (MGCD516) Featured | Sitravatinib (MGCD516) is a novel small molecule inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Kit, PDGFRβ, PDGFRα, c-Met, and Axl. |
|
| DC7501 | SKLB1002 Featured | SKLB1002 is a novel and potent VEGFR-2 inhibitor with an IC50 value of 32 nM. |
|
| DC7502 | SKLB610 Featured | SKLB610, a novel multi-targeted inhibitor, inhibits angiogenesis-related tyrosine kinase VEGFR2, FGFR2 and PDGFR at rate of 97%, 65% and 55%, respectively, at concentration of 10 μM in biochemical kinase assays. |
|
| DC9992 | Src kinase inhibitor I Featured | Src kinase inhibitor I is a potent competitive inhibitor of both Src and Lck (IC50 = 44 and 88 nM, respectively), as well as Csk and Yes. |
|
| DC10600 | SU 5205 Featured | SU 5205 is a VEGFR2 inhibitor. |
|
| DC10519 | SU 5214 Featured | SU 5214 is a modulator of tyrosine kinase signal transduction. |
|
| DC9794 | SU-10994 | SU-10994 is a novel VEGFR inhibitor. |
|
